featured
γ-Secretase Inhibitor Plus BCMA CAR T-Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial
Lancet Oncol 2023 Jul 01;24(7)811-822, AJ Cowan, MJ Pont, BD Sather, CJ Turtle, BG Till, EN Libby, DG Coffey, SA Tuazon, B Wood, T Gooley, VQ Wu, J Voutsinas, X Song, M Shadman, J Gauthier, AG Chapuis, F Milano, DG Maloney, SR Riddell, DJ GreenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.